Bluejay Diagnostics (BJDX) Competitors $3.42 -0.17 (-4.71%) As of 02:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesOwnershipSEC FilingsShort InterestTrends BJDX vs. PSTV, STRR, CTCX, NUWE, CHEK, TNON, SINT, TTOO, HSCS, and AMIXShould you be buying Bluejay Diagnostics stock or one of its competitors? The main competitors of Bluejay Diagnostics include Plus Therapeutics (PSTV), Star Equity (STRR), Carmell (CTCX), Nuwellis (NUWE), Check-Cap (CHEK), Tenon Medical (TNON), Sintx Technologies (SINT), T2 Biosystems (TTOO), Heart Test Laboratories (HSCS), and Autonomix Medical (AMIX). These companies are all part of the "medical equipment" industry. Bluejay Diagnostics vs. Plus Therapeutics Star Equity Carmell Nuwellis Check-Cap Tenon Medical Sintx Technologies T2 Biosystems Heart Test Laboratories Autonomix Medical Bluejay Diagnostics (NASDAQ:BJDX) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk. Is BJDX or PSTV more profitable? Bluejay Diagnostics has a net margin of 0.00% compared to Plus Therapeutics' net margin of -225.07%. Plus Therapeutics' return on equity of 0.00% beat Bluejay Diagnostics' return on equity.Company Net Margins Return on Equity Return on Assets Bluejay DiagnosticsN/A -155.67% -117.82% Plus Therapeutics -225.07%N/A -154.56% Do insiders and institutionals have more ownership in BJDX or PSTV? 18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 0.4% of Bluejay Diagnostics shares are owned by insiders. Comparatively, 5.5% of Plus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer BJDX or PSTV? Plus Therapeutics received 66 more outperform votes than Bluejay Diagnostics when rated by MarketBeat users. However, 66.67% of users gave Bluejay Diagnostics an outperform vote while only 62.39% of users gave Plus Therapeutics an outperform vote. CompanyUnderperformOutperformBluejay DiagnosticsOutperform Votes266.67% Underperform Votes133.33% Plus TherapeuticsOutperform Votes6862.39% Underperform Votes4137.61% Which has stronger valuation & earnings, BJDX or PSTV? Bluejay Diagnostics has higher earnings, but lower revenue than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBluejay Diagnostics$250K7.53-$9.95M-$1.37 thousand0.00Plus Therapeutics$4.91M1.44-$13.32M-$2.53-0.47 Which has more volatility & risk, BJDX or PSTV? Bluejay Diagnostics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Does the media refer more to BJDX or PSTV? In the previous week, Bluejay Diagnostics and Bluejay Diagnostics both had 1 articles in the media. Plus Therapeutics' average media sentiment score of 0.00 beat Bluejay Diagnostics' score of -1.00 indicating that Plus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Bluejay Diagnostics Negative Plus Therapeutics Neutral Do analysts recommend BJDX or PSTV? Plus Therapeutics has a consensus target price of $13.50, indicating a potential upside of 1,025.00%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Plus Therapeutics is more favorable than Bluejay Diagnostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Plus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPlus Therapeutics beats Bluejay Diagnostics on 10 of the 17 factors compared between the two stocks. Get Bluejay Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for BJDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BJDX vs. The Competition Export to ExcelMetricBluejay DiagnosticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.88M$4.68B$5.76B$9.17BDividend YieldN/A47.50%5.25%3.99%P/E Ratio0.0025.4226.1019.46Price / Sales7.5361.70456.3571.26Price / CashN/A50.3946.0638.90Price / Book0.006.527.305.06Net Income-$9.95M$89.44M$3.19B$222.54M7 Day Performance-6.27%2.05%2.22%2.30%1 Month Performance2.12%1.92%3.57%1.62%1 Year Performance-98.92%18.34%21.26%16.61% Bluejay Diagnostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BJDXBluejay Diagnostics0.2133 of 5 stars$3.42-4.7%N/A-98.9%$1.88M$250,000.000.009Short Interest ↑Negative NewsPSTVPlus Therapeutics2.2432 of 5 stars$1.22-1.3%$13.50+1,006.5%-38.0%$7.20M$4.91M-0.4820News CoverageGap DownSTRRStar Equity1.1004 of 5 stars$2.11+2.4%N/A-54.6%$6.79M$45.78M-0.82460CTCXCarmell1.7992 of 5 stars$0.28-9.2%N/A-93.3%$5.90MN/A0.0014Positive NewsNUWENuwellis2.4174 of 5 stars$1.33+4.7%$17.00+1,178.2%-93.9%$5.81M$8.86M-0.0170Gap UpCHEKCheck-Cap0.963 of 5 stars$0.90-2.2%N/A-59.8%$5.27MN/A-0.3080TNONTenon Medical1.6204 of 5 stars$1.46-2.3%$5.50+278.0%+19.7%$4.57M$2.93M-0.058SINTSintx Technologies0.6143 of 5 stars$3.06-5.6%N/A-89.8%$4.10M$2.63M-0.0640Gap DownTTOOT2 Biosystems1.7701 of 5 stars$0.19-7.4%$5.00+2,472.0%-98.9%$4.09M$7.68M0.00180News CoverageGap UpHigh Trading VolumeHSCSHeart Test Laboratories3.3673 of 5 stars$3.59-5.5%$13.50+276.0%-69.1%$3.52M$20,000.00-0.4510Short Interest ↓Gap UpAMIXAutonomix Medical2.5936 of 5 stars$2.72+0.7%$28.00+929.4%-96.2%$3.13MN/A-0.171Earnings Report Related Companies and Tools Related Companies Plus Therapeutics Alternatives Star Equity Alternatives Carmell Alternatives Nuwellis Alternatives Check-Cap Alternatives Tenon Medical Alternatives Sintx Technologies Alternatives T2 Biosystems Alternatives Heart Test Laboratories Alternatives Autonomix Medical Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BJDX) was last updated on 2/18/2025 by MarketBeat.com Staff From Our PartnersTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bluejay Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bluejay Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.